SCHEMBL24310681

SCHEMBL24310681

CC(C)c1ccccc1-c1nc(NS(=O)(=O)c2cccc(N)c2)nc(Cl)c1C(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.42
▸ PRMT1 Q99873 1/20 0.38
▸ CYP19A1 P11511 1/20 0.38
▸ PKM P14618 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ HTR6 P50406 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ CA12 O43570 1/20 0.36
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ PGR P06401 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ MAPT P10636 1/20 0.35
▸ CDC25A P30304 1/20 0.35
▸ CDC25B P30305 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29567037 1.00 POLB (0.42) POLBPRMT1CYP19A1PKMALDH1A1
SCHEMBL29567299 0.90 POLB (0.42) POLBPRMT1CYP19A1PKMALDH1A1
SCHEMBL24309373 0.90 POLB (0.42) POLBPRMT1CYP19A1PKMALDH1A1
SCHEMBL29566965 0.85 LMNA (0.46) CYP19A1ALDH1A1L3MBTL1KMT2AMAPT
SCHEMBL29567242 0.84 POLB (0.41) POLBPRMT1CYP19A1PKMHTR6
SCHEMBL26651221 0.84 POLB (0.41) POLBPRMT1CYP19A1PKMHTR6
SCHEMBL24310682 0.82 POLB (0.37) POLBPRMT1CYP19A1PKMALDH1A1
SCHEMBL29566908 0.82 POLB (0.37) POLBPRMT1CYP19A1PKMALDH1A1
SCHEMBL24309269 0.82 POLB (0.43) POLBPRMT1CYP19A1PKMALDH1A1
SCHEMBL29567210 0.82 POLB (0.43) POLBPRMT1CYP19A1PKMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B POLB 3593/4885PRMT1 3344/4885CYP19A1 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback